Regulator Reforms Coming Soon In Thailand?
This article was originally published in SRA
Thailand's public body TCELS (Thailand Center of Excellence for Life Sciences) and private companies are submitting proposals for the reform of the Thai FDA to make it more competitive with counterpart agencies in the region, notably the South Korean and Singaporean regulators, which are aggressive in providing fast turnaround times to attract businesses to their locations.
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.